Lipaglyn®

Lipaglyn is a novel drug used in the treatment of Diabetic Dyslipidemia. It is the first “Glitazar“ brand to receive approval and is the first New Chemical Entity (NCE) discovered and developed indigenously by an Indian Pharmaceutical Company. Lipaglyn is approved by the Drug Controller General Of India (DCGI). It has a dual mode of action on PPAR α and PPAR γ receptors, offers lipid and glucose-lowering effects in one molecule.